Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,500 shares of the company on 01-10-2025. This trade was reported by Quiver Quantitative using data from a ...
Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a ...
Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Greenwich LifeSciences (GLSI – Research Report) ...
NASDAQ:GLSI opened at $12.38 on Friday. Greenwich LifeSciences has a 52 week low of $9.91 and a 52 week high of $21.44. The firm has a market capitalization of $162.80 million, a PE ratio of -15. ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, on Wednesday, announced that its application seeking expansion of its FLAMINGO-01 clinical trial in ...
Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results